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Abstract: Despite the induction of effective immune responses, 80% of hepatitis C virus 
(HCV)-infected individuals progress from acute to chronic hepatitis.  In contrast to the 
cellular immune response, the role of the humoral immune response in HCV clearance is 
still subject to debate. Indeed, HCV escapes neutralizing antibodies in chronically infected 
patients and reinfection has been described in human and chimpanzee. Studies of   
antibody-mediated  HCV  neutralization have long been hampered by the lack of   
cell-culture-derived virus and the absence of a small animal model. However, the 
development of surrogate models and recent progress in HCV propagation in vitro now 
enable robust neutralization assays to be performed. These advances are beginning to shed 
some light on the mechanisms of HCV neutralization. This review summarizes the current 
state of knowledge of  the viral targets of anti-HCV-neutralizing antibodies and the 
mechanisms that enable HCV to evade the humoral immune response. The recent 
description of the HCV glycan shield that reduces the immunogenicity of envelope proteins 
and masks conserved neutralizing epitopes at their surface constitutes the major focus of 
this review. 
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1. Introduction 
The hepatitis C virus (HCV) is a major public health problem worldwide. More than 170 million 
people worldwide are seropositive for HCV and thus  risk developing  cirrhosis and hepatocellular 
carcinoma [1]. Indeed, HCV tropism is principally restricted to the liver and the HCV viral cycle has 
been shown to be tightly linked to the hepatocyte’s lipid metabolism. In particular, HCV particle 
production depends on assembly and secretion of very low-density lipoproteins and plasma-derived 
HCV particles have been reported to be in complex with low and very low-density lipoproteins [2–7]. 
However, the nature of the association between HCV and these lipoproteins remains unclear [8]. 
Today’s standard treatment for HCV infection is combination therapy with pegylated interferon and 
ribavirin [9]. However, this therapy is expensive, relatively toxic and effective in only half of treated 
patients. Specific, directly acting anti-HCV drugs are now entering the market and will hopefully soon 
provide  substantial improvements  over current treatments  [10]. The development of a protective 
vaccine against HCV has proven to be extremely challenging but is still being pursued, since it would 
constitute the most cost-effective means to reduce HCV spread to uninfected individuals. Extensive 
research in this area suggests that a successful HCV vaccine will need to stimulate: (i) the production 
of antibodies (Abs) that exhibit antiviral activity (also referred to as neutralizing Abs (NAbs)); and 
(ii) potent HCV-specific T cell responses. To this end, it is essential to define all the neutralizing 
determinants  displayed by  HCV envelope glycoproteins and particularly conserved structures that 
could  enable  cross-neutralization between diverse virus genotypes and minimize the likelihood of 
immune  escape.  It is also  important to understand the molecular basis of HCV resistance 
to neutralization. 
Despite the induction of effective immune responses, 80% of HCV-infected individuals progress 
from acute to chronic hepatitis. Spontaneous viral clearance occurs in approximately 20% of acutely 
infected individuals and results in the resolution of the infection without sequelae. It is believed that 
the type and strength of the host immune responses during the acute phase of HCV infection determine 
the outcome. The importance of CD4 and CD8 T cells in clearing HCV infection is widely accepted. In 
contrast, the role played by Abs in HCV clearance remains subject to debate.  Infection by HCV 
induces the production of Abs against various HCV proteins in the majority of chronically infected 
people. Moreover, NAbs have been detected in the sera of HCV-infected patients [11–17]. These 
NAbs may be classified as isolate-specific or cross-neutralizing,  depending on their ability to 
neutralize only the autologous virus or heterologous viral strains. 
Studying the relative contribution of Abs to HCV clearance has long been hampered by the lack of 
convenient in vitro models for evaluating the neutralizing activity of anti-HCV Abs. However, the 
development of retroviral particles pseudotyped with HCV envelope proteins (HCVpp) [12,18,19] and 
cell culture-derived HCV (HCVcc) [20–22] now enable sensitive and robust neutralization assays to be 
performed. Although HCVpp do not mimic all the complex features of native viral particles [23–28], 
in vitro  neutralization in the HCVpp model system usually correlates well with neutralization of Viruses 2011, 3                         
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infectious  HCVcc. Importantly, the very recent development of an immunocompetent,  genetically 
humanized mouse model, which recapitulates a part  of the HCV life cycle, is  opening  up  new 
opportunities for studying HCV neutralization in vivo [29]. 
Recent studies suggest that rapid induction of NAbs during the early phase of infection may help 
clear or control HCV infection [14,30,31]. However, doubt has been cast on the role of NAbs in host 
protection, since: (i) HCV is able to escape NAbs in chronically infected patients; and (ii) reinfection 
has been described in both humans and chimpanzees [32–34]. Mechanisms that enable HCV to evade 
the humoral immune response are starting to be elucidated and form the theme of this review. Here, we 
summarize recently accumulated knowledge on the viral targets of anti-HCV NAbs and anti-HCV 
NAbs escape strategies, with a special focus on our recent findings concerning the HCV glycan shield. 
2. HCV Envelope Glycoproteins 
2.1. HCV Envelope Glycoproteins and Viral Entry 
HCV is a small, enveloped, single-stranded positive RNA virus that belongs to the Hepacivirus 
genus within the Flaviviridae family and infects only humans and chimpanzees in vivo [1]. This virus 
displays a high degree of genetic heterogeneity and has been classified into seven genotypes and 
several subtypes. Its genome encodes a single polyprotein precursor of about 3,000 amino acid 
residues, which is cleaved co- and post-translationally by host and viral proteases to yield ten mature 
products [1]. The two envelope glycoproteins, E1 and E2, are released from the polyprotein by signal 
peptidase cleavages. These glycoproteins are type I membrane proteins with a C-terminal 
transmembrane domain anchored in the lipid envelope. These two proteins assemble as non-covalent 
heterodimers, which are mainly retained in the endoplasmic reticulum [35], and they are found as large 
disulfide-linked oligomers on the surfaces of HCV particles [36]. A high-resolution structure of HCV 
envelope proteins is still lacking but a schematic representation of the three-dimensional organization 
of E2, predicted by disulfide mapping and molecular modeling, was published recently [37]. This 
model proposes that the ectodomain is composed of three domains (Domains I, II and III) followed by 
a stem region  (Figure 1). Interestingly, functional studies have recently confirmed the bipartite 
composition of Domain I suggested by this model [27]. 
The HCV envelope glycoproteins E1 and E2 play an important role in the binding step of the entry 
process [38]. Indeed, HCV attaches to host cells via interactions between E1E2 and several cellular 
entry factors. Some studies suggest that glycosaminoglycans may serve as the initial docking site for 
HCV [39,40]. Although it has been suggested that the envelope proteins play a role in this interaction, 
involvement of the HCV-associated lipoproteins in the initial glycosaminoglycan binding cannot be 
ruled out [41]. In view of the association between HCV and lipoproteins, the LDL receptor has also 
been suggested as another potential attachment factor for HCV [42–44]. However, the role of this 
receptor in HCV entry remains unclear. After the initial attachment to the host cell, a virus generally 
binds to specific entry factors that are responsible for initiating a series of events leading to release of 
the viral genome into the cytosol. Several cell surface proteins have been described as specific entry 
factors for HCV and interactions with these molecules do appear to occur in a programmed series of 
events. The first identified and best characterized entry factor is the tetraspanin CD81, which was Viruses 2011, 3                         
 
 
1912 
initially shown to interact with HCV glycoprotein E2 [45] (for a review, see [46]). Several E2 residues 
involved in the CD81 interaction have been identified (Figure 1) [47–49]. 
Figure 1. Localization of the N-linked glycans on the model of hepatitis C virus (HCV) E2 
glycoprotein (modified version of the figure published by Helle et al. [28], adapted from 
the model recently published by Krey et al. [37]). The linear sequence of the JFH-1 strain 
E2 ectodomain without the stem region is represented as a chain of beads (colored circles) 
labeled with the corresponding amino acid and threaded onto a class II fold. The three 
putative domains are presented in red (DI), yellow (DII), and blue (DIII), and the variable 
regions (HVR1, HVR2, and IgVR) are indicated in brown. Circles in pale and bright colors 
represent residues in the background and foreground of the domains, respectively. 
Disulfide bonds are indicated by black bars. DI domain residues that are involved in CD81 
binding [48] are outlined in blue. Amino acids recognized by known anti-HCV monoclonal 
neutralizing antibodies (NAbs) (Table 1) are shown as grey circles. Glycosylation sites are 
shown as sequentially-numbered green circles. Glycosylation sites masking the CD81 
binding site are highlighted with light green shading. 
 Viruses 2011, 3                         
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Table 1. The main anti-HCV monoclonal NAbs with available mapping information. 
Monoclonal 
NAb 
Specificity  Epitope * 
Residues Involved in 
Epitope Formation * 
References 
Anti-E1         
IGH505  Cross-reactive  313–326  316, 320, 323  [50,51] 
IGH526  Cross-reactive  313–326  316, 319, 320, 323, 324  [50,51] 
H-111  Cross-reactive  192–202  195, 196, 198, 199, 201  [52,53] 
         
Anti-E2         
3C7  H strain  HVR1–396–407    [54] 
9/27  H strain 
HVR1–396–407 
(partially conformation-dependent) 
  [19,55] 
AP213  Gla strain 
HVR1–396–407 
(partially conformation-dependent) 
400, 403, 404  [56] 
J6.36  J6 strain 
HVR1 
(partially conformation-dependent) 
403, 406  [57] 
3/11  Cross-reactive 
412–423 
(partially conformation-dependent) 
415, 420, 421  [19,55,58,59] 
AP33  Cross-reactive 
412–423 
(partially conformation-dependent) 
413, 415, 418, 420  [58,59] 
HCV1  Cross-reactive  412–423  413, 420  [60] 
H77.39  Cross-reactive  Located between 384–520  415, 417  [57] 
1:7  Cross-reactive  Conformational  523, 529, 530, 535  [23] 
A8  Cross-reactive  Conformational  523, 529, 530, 535  [23] 
CBH-2  Cross-reactive  Conformational 
425, 426, 431, 523, 529, 
530, 535 
[61] 
CBH-5  Cross-reactive  Conformational  523, 525, 530, 535  [62] 
CBH-7  Cross-reactive  Conformational  549  [62] 
HC-1  Cross-reactive  Conformational  529, 530, 535,  [61] 
HC-12  Cross-reactive  Conformational  530, 535  [61] 
AR3A  Cross-reactive  Conformational 
424, 523, 525, 530, 535, 
540 
[63] 
AR3B  Cross-reactive  Conformational  424, 530, 535  [63] 
AR3C  Cross-reactive  Conformational  424, 525, 530, 535, 540  [63] 
AR3D  Cross-reactive  Conformational  424, 530  [63] 
H35 
Poorly cross-
reactive 
Conformational 
523, 527, 529, 530, 535, 
550 
[12,48] 
H48 
Poorly cross-
reactive 
Conformational  523, 529, 530, 535, 550  [12,48] 
* The numbers correspond to the positions in the polyprotein of the reference strain H (GenBank accession no. AF009606). 
 
Following the identification and characterization of CD81 as a molecule involved in HCV entry, 
HCV glycoprotein E2 was found to also interact with the human scavenger receptor class B type I 
(SR-BI, also referred to as CLA-1). Hence, SR-BI has also been suggested as a potential entry factor 
for HCV [64,65]. It appears that HCV exploits SR-BI physiological functions during the entry process Viruses 2011, 3                         
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(for  a review, see [66]). The  kinetics of infection inhibition with anti-SR-BI- and anti-CD81-Abs 
suggest that SR-BI is involved in virus/cell recognition upstream of the CD81 interaction [67,68]. 
Indeed, it is likely that the HCV particle encounters SR-BI before CD81, since it can bind to CHO 
cells expressing SR-BI but not to CHO cells expressing CD81 [69].  The  hypervariable region 1 
(HVR1) in E2 is important for interaction with SR-BI [64,70,71] and it has recently been suggested 
that HVR1 masks the CD81 binding region [71]. Thus, initial contact with SR-BI may be needed to 
unmask the CD81 binding region on E2 and thus enable the particle to interact with CD81. Although a 
direct interaction between HVR1 and SR-BI could take place, it has also been suggested that the 
lipoproteins associated with the viral particle interact with this entry factor [72]. Indeed, SR-BI is also 
a receptor for low-density lipoproteins [73]. Whether this indirect interaction plays a role in HCV 
entry, however, remains to be determined. 
Recently, the tight junction proteins Claudin-1 (CLDN1) and Occludin (OCLN) have been 
identified as additional entry factors for HCV [69,74]. CLDN6 and 9 are also able to mediate HCV 
entry [75,76]. The interaction between CLDN and CD81 seems to be important for HCV entry process 
[77–79] and is regulated by receptor tyrosine kinases EGFR and EphA2 [80]. Furthermore, indirect 
E2-OCLN association was demonstrated in  co-immunoprecipitation and pull-down assays [81,82]. 
However, a direct interaction between CLDN or OCLN molecules and HCV envelope glycoproteins 
has not yet been reported [83]. Thus, the precise role of CLDN and OCLN proteins in HCV entry 
remains to be determined. 
HCV enters target cells via clathrin-mediated endocytosis [84] and it has been suggested that fusion 
occurs in the early endosomes [85]. The endosomes acidic pH has been shown to trigger the fusion 
process, probably by inducing conformational changes in the envelope proteins [19,40,70,84–86]. The 
precise roles of E1 and E2 in the fusion step have not yet been determined. It has been suggested that 
amino acids 262–290 in E1 as well as 416–430, 502–520 and 600–620 in E2 play a role in the fusion 
process and it could be that both proteins are involved in this process [37,87-94]. It has also been 
reported that E2 can bind lipid membranes devoid of proteins after acidic treatment, which suggests a 
direct role for this protein in the fusion process [95]. Interestingly, the transmembrane domains of 
HCV envelope glycoproteins also play an active role in the fusion process. Indeed, mutations in these 
domains affect the fusion properties of HCV envelope glycoproteins, possibly by affecting the 
oligomeric reorganization of the fusion protein [96]. After fusion between the viral envelope and an 
endosomal membrane, the viral genome is released into the cytosol. 
Interestingly, it was recently reported that the host neutralizing responses in HCV-infected patients 
target viral entry after HCV binding  and are most likely related to HCV-CD81  and  HCV-SR-BI 
interactions or membrane fusion [51]. 
2.2. Neutralizing Determinants in HCV Envelope Glycoproteins 
The NAb major target is the E2 envelope glycoprotein. The first neutralizing epitopes on HCV 
envelope glycoproteins to be described were  located  within HVR1 [97]. Statistical analyses have 
suggested the presence of two immunogenic domains in  HVR1,  encompassing the N-terminal  
part and the C-terminal part, respectively  [98]. However, anti-HVR1 Abs are often  partially  
conformation-sensitive  [55–57]. Data obtained with various anti-HVR1 Abs suggest that the   Viruses 2011, 3                         
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C-terminal region is the main neutralization determinant in HVR1 [13,19,54,56,57]. Indeed, the rat 
anti-HVR1 monoclonal Abs (mAbs) 6/16, 7/59 and 6/82, which bind to the N-terminal part of HVR1, 
do not neutralize HCV infectivity [19]. In contrast, mAbs 9/27, 3C7, J6.36 and AP213, as well as the 
polyclonal Abs R140 and R1020, whose target  epitopes include the C-terminal part of HVR1, 
neutralize HCV infection [13,19,54,56,57]. Detailed mapping identified residues at positions 400, 403, 
404 and 406 as key epitope residues for J6.36, AP213, R140 and R1020 (Figure 1 and Table 1) 
[56,57]. Abs directed against HVR1 may neutralize HCV by blocking the interaction between E2 and 
SR-BI, as described for the 9/27 and J6.36 mAbs [57,64]. However, while there is strong evidence to 
suggest  that NAbs directed against  HVR1 correlate with a beneficial outcome, these Abs usually 
present limited cross-reactivity. 
In contrast, a number of groups have pointed out the potential existence of additional neutralizing 
epitopes elsewhere in the E2 glycoprotein by describing Abs with a broader neutralizing activity 
[13,16,99]. In particular, several discontinuous regions of E2 contain highly conserved residues 
involved in CD81 binding and are targeted by NAbs [48]. Several studies have described monoclonal 
NAbs directed against these broadly conserved epitopes in different HCV genotypes [57,58,100]. For 
instance, the mouse AP33 mAb and the rat 3/11 mAb have broad neutralizing activity that can be 
attributed to the extreme conservation of their epitopes and the importance of the targeted region in 
CD81 binding [57,58,100]. Human mAbs recognizing conserved neutralizing epitopes on E2 envelope 
proteins, that are of greater  interest for the development of  therapeutic strategies, have also been 
described by several groups [23,60,63,101–106]. Detailed mapping and selection of escape variants 
identified residues at positions 415, 420, 424, 523, 525, 529, 530 and 535 as key residues involved in 
the corresponding neutralizing epitopes (Figure 1 and Table 1) [23,57–63,105,107]. Many of these 
residues are also important for E2 binding to CD81 (Figure 1) [47–49]. This cluster of overlapping 
neutralizing epitopes, referred to as “domain B” by Steven Foung’s group and located in Domain I of 
the HCV E2 structural model (Figure 1), is conserved across most HCV genotypes and thus is an 
attractive target for vaccine design. 
E1-specific NAbs have also been described but are rare, probably due to the poor immunogenicity 
of this protein or the immunodominance of E2. An E1-specific serum has been shown to neutralize 
HCVpp and HCVcc [53,108]. Furthermore, three human mAbs recognizing neutralizing epitopes on 
E1 have been described: H-111, which has moderate neutralizing activity [52,53], IGH520 (a sister 
clone of IGH505) and IGH526, which neutralize numerous HCV genotypes [50,51]. This shows that 
neutralizing epitopes in E1 are targeted by host responses in vivo. In particular, the H-111 epitope is 
located in the amino-terminal  portion of E1 (amino acids 192–202; Table 1)  [52]. Furthermore, 
Haberstroh et al. showed that the region corresponding to amino acids 313–326 is targeted by IGH520 
and IGH526 during postbinding events (Table 1) [51]. 
3. Evasion of the Humoral Immune Response 
The ability of HCV to persist in its host in the presence of NAbs has yet to be explained. Several 
mechanisms by which HCV could evade the host humoral immune response have been suggested 
(see [109]  for  a  detailed review). It is thought  that the high variability of HCV  genomic RNA 
represents a first escape strategy. Typically, the presence of different but closely related viral variants Viruses 2011, 3                         
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within the same individual (commonly defined as “quasispecies”) may allow the virus to circumvent 
the immune response [110–113]. However, it has long been difficult to assay NAbs activity against 
viral variants present in patient sera at the time of sample collection. Two recent studies looked at 
envelope glycoprotein sequence evolution and neutralization of sequential autologous HCVpp and 
found that HCV continuously escapes the host neutralizing response by mutations resulting in loss of 
NAb binding to HCV envelope glycoproteins [31,114]. This finding  suggests that the host  NAb 
response lags behind the rapidly evolving HCV envelope glycoprotein sequences in the quasispecies 
population.  To be more precise, several studies have  demonstrated that envelope gene evolution, 
particularly in the HVR1, is shaped by NAb pressure and occurs as a direct response to immune 
pressure from NAbs [31,114–116]. Interestingly, it has been observed that HVR1 can remain stable for 
up to 21 months without NAb pressure but shifts from its initial sequence after initiation of a NAb 
response [116]. Importantly, the infection outcome in humans can be predicted by sequence changes in 
E2 HVR1 [117]. Recently, it has also been suggested that HVR1 obstructs the viral CD81 binding site 
on E2 and decreases  the  exposure of crucial conserved epitopes,  thus preventing effective 
neutralization [71,118]. Thus, HVR1 may act as an immunological decoy that diverts the immune 
system and shields conserved neutralizing epitopes. The lipoproteins associated with the virions could 
also protect HCV against NAbs [2,72,119,120]. In particular, a correlation was observed between 
HCVcc density and sensitivity to neutralizing immunoglobulin G, suggesting that lipoproteins reduce 
the sensitivity of particles to NAbs [119]. Furthermore, high-density lipoproteins have also been shown 
to attenuate the neutralization of HCVpp by Abs from HCV-infected patients by accelerating HCV 
entry [53,121,122]. Cell-to-cell transmission could also prevent HCV from being recognized by NAbs 
once an infection is established [123–126].  Lastly, the presence of interfering Abs  has also been 
described [127,128]. These Abs disrupt virus neutralization mediated by Abs recognizing residues 
412–426 on E2 by binding to non-neutralizing epitopes at residues 434–446. 
4. The HCV Glycan Shield 
The ectodomains of HCV envelope glycoproteins are highly glycosylated. E1 contains four 
conserved N-glycosylation sites (E1N1 to E1N4; positions 196, 209, 234 and 305 in the  H77 
strain) [129]. Other sites are conserved in only some genotypes: position 250 in genotypes 1b and 6 
and position 299 in genotype 2b. Nine glycosylation sites in E2 are conserved across all genotypes 
(E2N1, E2N2, E2N3, E2N4, E2N6, E2N8, E2N9, E2N10 and E2N11; positions 417, 423, 430, 448, 
532, 556, 576, 623 and 645 in the H77 strain) (Figure 1) [129]. A site at position 476 (E2N5) exists in 
most genotypes but is rarely present in genotype 1b sequences. Another site at position 540 (E2N7) is 
absent in genotypes 3 and 6. Thus, despite variability in HCV envelope glycoprotein sequences, most 
E1E2 N-glycosylation sites are highly conserved, suggesting that the glycans associated with these 
proteins play an essential role in the HCV life cycle. Importantly, all these sites have been shown to be 
modified by glycans [130].  Potential  O-glycosylation sites have  also been predicted on the E2 
envelope protein [131]. However, mass spectrometry analysis of the E2 ectodomain did not reveal the 
presence of O-glycans [132]. 
Site-directed mutagenesis in HCVpp or HCVcc systems has  enabled  researchers  to study the 
functional role of the N-glycans associated with HCV envelope proteins (see Table 2 for a summary). Viruses 2011, 3                         
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The results indicate that several glycans have an important role in virion assembly and infectivity 
[28,130,131]. Indeed, mutation of glycosylation sites E1N1, E2N8 or E2N10 leads to envelope protein 
instability and virion assembly defects [28]. Interestingly, these mutations also lead to a decrease in 
recombinant E1E2 heterodimerization and affect the incorporation of envelope proteins at the HCVpp 
surface [130]. These results indicate that glycans E1N1, E2N8 and E2N10 are important for E1E2 
folding and heterodimerization and thus for virion assembly. Surprisingly, mutation of glycosylation 
site E1N4,  which also leads to a decrease of recombinant E1E2 stability, heterodimerization and 
incorporation on HCVpp [130], had only a slight effect on HCVcc infectivity [28]. 
Table 2. Summary of the properties of glycosylation mutants. 
Virus  HCVcc Infectivity 
a  HCVpp Infectivity 
a,b  Core Release 
c  Sensitivity to Neutralization 
d 
Wild-type  +++  +++  ++  + 
Mutant         
E1N1  +/–  ++  −  ND (+) 
E1N2  ++  +  +  ND (+) 
E1N3  +++  ++  ++  ND (+) 
E1N4  ++  +  +/–  ND (+) 
E2N1  +++  ++  ++  ++ 
E2N2  ++  – (–)  ++  ++
e 
E2N3  +  +++  +  ND (+) 
E2N4  ++  – (–)  +  ++
e 
E2N5  ++  ++  ++  + 
E2N6  +++  ++  ++  ++ 
E2N7  +/–  +++ (+)  +  ND (–) 
E2N8  –  –  +/–  ND 
E2N9  +++  +++  ++  + 
E2N10  –  –  –  ND 
E2N11  +  +  +/–  ++ 
a  Percentage of infectivity: +++, >90%; ++, between 30% and 90%; +, between 10% and 30%; 
+/−, between 2% and 10%; −, <2%. 
b  Infectivity of HCVpp of genotype 1a, as previously reported [130]. The values in brackets are 
the results obtained for genotype 2a HCVpp. 
c  Percentage of core release: ++, >75%; +, between 30% and 75%; +/−, between 12% and 30%;  
−, <12%. 
d  Sensitivity to antibody neutralization: +, similar to wild-type; ++, more than a 5-fold increase in 
sensitivity to neutralization with most antibodies tested; −  decrease in sensitivity to 
neutralization. The values in brackets were obtained for genotype 1a HCVpp only [129].  
ND, not determined. 
e  Results obtained with the HCVcc system only. 
 
Glycans associated with viral envelope proteins can modulate the latter’s  entry functions  by 
modifying the affinity for one or more receptors or by affecting fusion activity. It has been observed 
that the loss of glycan at position E2N6 increases the infectivity of HCVcc [28]. Furthermore, this 
mutant is also more sensitive to inhibition by a soluble form of the CD81 large extracellular loop. 
Lastly, it has been shown that a soluble form of E2 lacking glycan at position E2N6 exhibits a higher Viruses 2011, 3                         
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affinity for CD81 than the native molecule [131]. Overall, these data suggest that the better fitness of 
E2N6 mutant in vitro is due to a stronger interaction with CD81. Interestingly, the emergence of 
adaptive mutations leading to the loss of the E2N6 glycosylation site has  been observed in cell  
culture [133,134]. In contrast, mutation of the E2N7 glycosylation site leads to a strong decrease in 
HCVcc infectivity but does not affect viral particle secretion [28]. Thus, it seems that glycan E2N7 is 
located in a key region of E2 that modulates viral entry. However, this modulation is probably 
genotype-specific since the site is absent in genotypes 3 and 6. The observed differences between 
genotypes 1a and 2a HCVpp agree with this hypothesis [28,130,131]. 
It is noteworthy that for some mutants, the envelope glycoprotein entry functions are differently 
affected by glycan loss in HCVcc and HCVpp systems [28]. In particular, mutation of the E2N2 or 
E2N4 glycosylation sites had only a slight effect on HCVcc infectivity, whereas the same mutations 
led to the secretion of non-infectious  HCVpp. These discrepancies are probably  due to assembly 
process differences between HCVpp and HCVcc [3,135], which could be responsible for differences in 
glycan processing [36] and/or differences in the organization of HCV envelope proteins at the surface 
of the particle [35,36]. Lastly, an effect of HCVcc-associated lipoproteins on the properties of the 
envelope proteins cannot be ruled out  [3,136]. Differences between  the entry functions of HCV 
envelope glycoproteins in HCVpp and HCVcc have been reported elsewhere [23–27]. 
Interestingly, we recently used the HCVcc system to demonstrate that at least five glycans on E2 
(E2N1, E2N2, E2N4, E2N6 and E2N11) reduce HCVcc sensitivity to neutralization. This indicated 
that glycans limit the recognition of neutralizing epitopes at the surface of E2 (Figure 1) [28]. Indeed, 
the absence of one of these glycans leads to a higher sensitivity to neutralization by Abs purified from 
the  sera of HCV  seropositive patients,  as well as mAbs. These data are in agreement with those 
obtained in the HCVpp system for E2N1, E2N6 and E2N11 mutants [129,131]. The E2N2 and E2N4 
mutant sensitivity to neutralization could not be tested in the HCVpp system, since the corresponding 
mutations lead to the production of non-infectious pseudoparticles. Interestingly, our results suggest 
that neutralizing epitopes located in HVR1 are not masked by E1E2 associated glycans, since the 
mutation of glycosylation sites did not modify the sensitivity of HCVpp to neutralization with mAbs 
9/27 and 3C7 directed against this region [129]. In contrast, glycans E2N1, E2N2, E2N4, E2N6 and 
E2N11 modulate the neutralizing activity of mAbs directed against conserved epitopes. In addition, 
E2N1, E2N2, E2N4 and E2N6 also modulate the inhibition of HCV infectivity by a soluble form of 
CD81, suggesting that the CD81 binding site on E2 is the NAb target that is protected by glycans. It 
remains to be determined whether the glycans and HVR1 shielding effects for the CD81 binding site 
are additive. To answer this question, it would be useful to test the sensitivity of the corresponding 
mutants in the context of HVR1-deleted HCV. 
Using HCVpp and purified Abs from HCV-seropositive patients, we did not observe any effect of 
E1 glycosylation mutations on sensitivity to neutralization [129]. This suggests that either neutralizing 
epitopes on E1 are not protected by glycans or the neutralizing immune response against HCV is 
dominated by anti-E2 Abs. To discriminate between these two possibilities, it would be interesting to 
study the sensitivity of E1 glycosylation mutants to anti-E1 neutralizing mAbs. In particular, glycans 
E1N1 and E1N2, located in the region recognized by mAb H-111, are not required for Ab binding, 
since successful competition for binding with synthetic peptides has been demonstrated. However, 
whether a lack of these glycans increases sensitivity to neutralization has not been yet determined. Viruses 2011, 3                         
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In addition to modulating the accessibility of the CD81 binding region, HCV glycans could also 
reduce access to other protein regions. Indeed, one third of the molecular mass of E1E2 heterodimers 
corresponds to glycans. Thus, it is likely that the presence of glycans at the surface of HCV particles 
limits the immunogenicity of the envelope proteins. The observation that the anti-E1 humoral   
immune response is stronger after mutation of glycosylation site E1N4 argues  in favor of this   
hypothesis  [137,138].  It has not yet been determined whether the glycans that protect the CD81 
binding region from NAb recognition also limit the immunogenicity  of this region. It would be 
interesting to see whether the use of the E2 glycosylation mutants, rather than fully glycosylated E2, 
could enhance the production of NAbs. Thus, in addition to the mechanisms described in the previous 
section, the presence of glycans at the surface of HCV envelope proteins could help explain how HCV 
evades the humoral immune response and why most HCV infections lead to chronicity. 
5. Conclusions and Perspectives 
In conclusion, recent research has provided much insight into HCV-neutralizing epitopes and the 
virus ability to evade the humoral immune response. Several data evidence that HCV envelope protein 
N-glycans mask conserved neutralizing epitopes at the surface of HCV particles and also limit 
envelope  protein immunogenicity. Many viruses that impact human health, including HIV and 
influenza, use glycosylation for immune evasion, since glycans are synthesized by the host cells and 
are basically self-structures [139]. HIV is one of the most studied viruses with respect to glycosylation 
and its gp120 envelope protein is one of the most heavily glycosylated proteins in nature, with an 
average of 25 potential N-linked glycosylation sites (range:  18–33)  [140].  Hence, glycosylation 
accounts for roughly 50% of gp120 molecular mass. Free gp120 glycoproteins have three antigenic 
faces: (i) the non-neutralizing face, recognized by Abs that bind to epitopes not exposed in the context 
of the functional trimer; (ii) the neutralizing face, which binds most known NAbs; and (iii) the silent 
face which is composed of variable determinants, is heavily glycosylated and thus is poorly 
immunogenic [141–143]. Concerning influenza virus, N-glycosylation of the hemagglutinin (HA) and 
neuraminidase surface proteins is of major importance in biosynthesis, stability, virus release, receptor 
binding, infectivity and neurovirulence [139,144]. The number of N-glycosylation sites in HA, the 
major target of influenza virus NAbs, reportedly ranges from 5 to 11 [139]. Glycans located in the 
stalk region of the HA contribute to the folding, stability, trimerization and transport of HA molecules 
to the cell surface and thus are highly conserved. In addition, it is well established that glycans located 
at  HA  globular head can modulate the  immune recognition of influenza viruses by masking or 
modifying antigenic sites. 
Intriguingly, although HCV, HIV and the influenza virus share the common feature of shielding 
neutralizing epitopes with glycans, some differences related to the evolution of the glycan shield have 
been detected [140]. Indeed, variation in the number and location of glycosylation sites in the globular 
head of influenza HA could arise by antigenic drift, in order to prevent recognition of epitopes targeted 
by NAbs elicited by previously circulating strains. For instance, it has been observed that the number 
of sequons (i.e., potential glycosylation sites) in HA in the pandemic H3N2 virus increased from 6 to 
10 between 1968 and 2000, which makes  it more refractory to Abs recognition [145].  For  HIV, 
modification of the glycan shield under immune pressure in each infected patient seems to prompt an Viruses 2011, 3                         
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immune escape mechanism that allows the virus to persist despite the presence of an evolving Ab 
repertoire [143]. Apparently, there is immune-mediated selection pressure to both change the position 
of individual glycans and conserve gp120 overall glycan shield, since mutations that both destroy and 
create N-glycosylation sites are selected. Two kinds of sequons have been evidenced in HIV: (i) fixed 
sites (embedded in readily aligned positions); and (ii) shifting sites that shift in relative position and 
regional density due to point mutations, insertions or deletions [140]. Of course, this evolution is 
driven by the need to protect the adjacent, neutralizing epitopes. However, it may also be a mechanism 
to continually destroy non-self patterns formed by multiple glycans, which would be interpreted as a 
danger signal by the innate and adaptive immune systems as illustrated by the existence of the 
monoclonal NAb 2G12, which recognizes a cluster of glycans on gp120 silent face. Although HCV is 
an extraordinarily variable virus, N-glycosylation sites in HCV E1E2 proteins are far less variable than 
in HIV gp120 and influenza HA. Indeed, 13 of the 17 potential sequons are found in almost 100 % of 
E1E2 sequences [129]. Furthermore, only two shifting sites have been observed in E2, E2N5 and 
E2N9 [140], which are located in HVR2 and the intergenotypic variable region (IgVR), respectively 
(Figure 1) [146,147]. Hence, in contrast to HIV and influenza, the HCV glycan shield does not appear 
to be evolving. 
Taken as a whole, these data emphasize the importance of targeting carbohydrate antigens on the 
virus surface in vaccine and/or therapeutic strategies. It has long been thought that the glycosylation 
status of viral envelope proteins can explain the poor immune control by hosts in several infectious 
diseases. Many studies have suggested that understanding the role of glycosylation is critical for: 
(i) defining the virological properties and immunogenicity of viral envelope proteins; and (ii) designing 
carbohydrate mimetics  that  could be used as immunogens in  vaccine development [148,149]. 
Understanding the three-dimensional organization of the sugars on viral envelope proteins could guide 
the selection of mutants with the fewest antigenic and functional alterations but with enhanced 
neutralization sensitivity. Furthermore, it is now well-established that carbohydrate binding agents can 
inhibit viral entry of numerous viruses including HCV by binding to envelope protein glycans and 
preventing interactions between viral envelope proteins and specific cell surface receptors [150–152]. 
Pradimicin A is of particular interest for the development of new therapeutic strategies, as it is a small, 
non-peptidic compound that is likely to be less immunogenic and more stable than the lectins [151,153]. 
These observations suggest that it will be possible to design small antiviral molecules that target viral 
envelope protein glycans. Resistance to this type of drug is likely to develop and will probably result in 
mutations at some glycosylation sites and thus come at a replicative cost to the virus, as observed for 
HIV [154–156]. It has been argued that this strategy could be very efficient, since these compounds 
could not only directly inhibit viruses, but also induce partial loss of the glycan shield and make the 
virus more vulnerable to attack by the immune system [157,158]. 
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